Longeveron Inc (LGVN)

$0.79 +0.02 (3.02%)
Market Cap 16.12M
Revenue (ttm) 2.39M
Net Income (ttm) -15.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -668.20%
Debt to Equity Ratio 0.00
Volume 489,900
Avg Vol 999,284
Day's Range N/A - N/A
Shares Out 21.06M
Stochastic %K 63%
Beta 0.16
Analysts Strong Sell
Price Target $6.86

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
WallStVisions
WallStVisions Oct. 3 at 1:06 PM
If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:56 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BABA $LIDR $LGVN $SMMT odd
0 · Reply
HoldingontoPennies
HoldingontoPennies Oct. 1 at 8:10 PM
$LGVN 😘
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
judgeyoung2
judgeyoung2 Sep. 29 at 4:11 PM
$LGVN i picked up shares here
0 · Reply
babakbb
babakbb Sep. 29 at 11:11 AM
$LGVN Starter position. 10% insider ownership makes me think they won't dilute it further down but NFA anything possible.
1 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 28 at 6:11 PM
IVDA i think can be the next $1 to double digits stock. AI stocks are everywhere ....but none are doing what IVDA is doing. This company is integrating edge computing with physical hardware to actively prevent threats before they happen. It’s criminal how undervalued this is at current levels. $LGVN $OTLK $ONFO $PRPH $VIRI
0 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 27 at 12:03 AM
IVDA is one of the only low-float stocks tied to AI surveillance, autonomous drones, and threat detection. If you think robotics, safety, and government tech will scale, you’re looking at one of the earliest and cheapest ways to play it. Zero hype. Max upside. $EYEN $PALI $LGVN $QNRX $NGM
0 · Reply
MoneyorBagHolder
MoneyorBagHolder Sep. 26 at 1:34 PM
$LGVN is scheduled to participate in the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa taking place October 6-8, 2025 in Phoenix, Arizona. I have a small position with $LGVN and will hold at least until Oct 6-8.
0 · Reply
Gutshot71
Gutshot71 Sep. 19 at 11:56 PM
$LGVN Starting to wonder if this company actually does anything except raise $ for their bonuses. Can't believe I've been in this shit for about 5 years. If anyone is thinking about DCA or starting a position you might as well light your $ on fire.
2 · Reply
Latest News on LGVN
Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 12 days ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 4 weeks ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 6 weeks ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 10:55 PM EDT - 7 weeks ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 7 weeks ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 7 weeks ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 2 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 2 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 2 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 3 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 3 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 3 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 5 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025, 5:31 PM EDT - 5 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 5 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 5 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 7 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 7 months ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:04 PM EST - 7 months ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 7 months ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 8 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 10 months ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 10 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:37 PM EST - 11 months ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 11 months ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 11 months ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:58 PM EDT - 1 year ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Neha Motwani Elected to Longeveron® Board of Directors

Jul 9, 2024, 9:00 AM EDT - 1 year ago

Neha Motwani Elected to Longeveron® Board of Directors

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Jul 8, 2024, 9:00 AM EDT - 1 year ago

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Jun 18, 2024, 4:48 PM EDT - 1 year ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Jun 17, 2024, 9:00 AM EDT - 1 year ago

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Jun 17, 2024, 8:38 AM EDT - 1 year ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Why has Longeveron stock tripled in two days?

Jun 13, 2024, 9:45 AM EDT - 1 year ago

Why has Longeveron stock tripled in two days?

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024

May 28, 2024, 8:05 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2024

WallStVisions
WallStVisions Oct. 3 at 1:06 PM
If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:56 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BABA $LIDR $LGVN $SMMT odd
0 · Reply
HoldingontoPennies
HoldingontoPennies Oct. 1 at 8:10 PM
$LGVN 😘
0 · Reply
UtahSUV
UtahSUV Sep. 30 at 5:11 AM
$LGVN $KTTA i just want to say fuck you both
0 · Reply
judgeyoung2
judgeyoung2 Sep. 29 at 4:11 PM
$LGVN i picked up shares here
0 · Reply
babakbb
babakbb Sep. 29 at 11:11 AM
$LGVN Starter position. 10% insider ownership makes me think they won't dilute it further down but NFA anything possible.
1 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 28 at 6:11 PM
IVDA i think can be the next $1 to double digits stock. AI stocks are everywhere ....but none are doing what IVDA is doing. This company is integrating edge computing with physical hardware to actively prevent threats before they happen. It’s criminal how undervalued this is at current levels. $LGVN $OTLK $ONFO $PRPH $VIRI
0 · Reply
CarolinesCurrency
CarolinesCurrency Sep. 27 at 12:03 AM
IVDA is one of the only low-float stocks tied to AI surveillance, autonomous drones, and threat detection. If you think robotics, safety, and government tech will scale, you’re looking at one of the earliest and cheapest ways to play it. Zero hype. Max upside. $EYEN $PALI $LGVN $QNRX $NGM
0 · Reply
MoneyorBagHolder
MoneyorBagHolder Sep. 26 at 1:34 PM
$LGVN is scheduled to participate in the Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa taking place October 6-8, 2025 in Phoenix, Arizona. I have a small position with $LGVN and will hold at least until Oct 6-8.
0 · Reply
Gutshot71
Gutshot71 Sep. 19 at 11:56 PM
$LGVN Starting to wonder if this company actually does anything except raise $ for their bonuses. Can't believe I've been in this shit for about 5 years. If anyone is thinking about DCA or starting a position you might as well light your $ on fire.
2 · Reply
DARKP00L
DARKP00L Sep. 19 at 8:51 PM
$LGVN 16:48 on Sep. 19 2025 Longeveron Entered Into Sales Agreement For Sale Of Shares Of Class A Common Stock For Up To $10.7M From Time To Time #tradeideas
0 · Reply
stoxx0007
stoxx0007 Sep. 17 at 4:57 PM
$LGVN = what? 🤫
1 · Reply
Pipelinepivots
Pipelinepivots Sep. 14 at 3:59 AM
MITQ is in prime breakout territory: Golden cross forming, float nearly nonexistent, and no one’s paying attention yet. This setup screams stealth runner. If a headline drops, this won’t move it’ll gap. $INM $OBSV $LGVN $BTTX $AKAN
0 · Reply
Mervolo
Mervolo Sep. 12 at 8:01 PM
$ATCH fingers crossed peeps! I remember when $LGVN ran on a fri ah
0 · Reply
D3Squire
D3Squire Sep. 10 at 12:34 PM
$LGVN looking to breakout to 0.90 this week then it has room to run
0 · Reply
gr8whitenorth
gr8whitenorth Sep. 10 at 6:14 AM
$LGVN waiting for the pump 🦍🚀🌚
0 · Reply
janlukas
janlukas Sep. 9 at 1:00 PM
$LGVN Cwd + 2200% now in pre market without any news, from $2 yesterday it is now $50, it will probably touch $100 during the day. We have the science, it's time for big spikes, come on, let's do it!
2 · Reply
ACInvestorBlog
ACInvestorBlog Sep. 8 at 4:34 PM
$LGVN some hits 🤔
1 · Reply
HoldingontoPennies
HoldingontoPennies Sep. 8 at 4:28 PM
$LGVN
1 · Reply
janlukas
janlukas Sep. 8 at 2:57 PM
$LGVN Today, Octo went from $1.45 to $55, or 3000%. Come on, there's some science here, let's do it!
0 · Reply
janlukas
janlukas Sep. 8 at 1:25 PM
$LGVN Today Octo plus 1000% at the opening we can do it here too, the news could be explosive.
1 · Reply
PHILMYWALLET
PHILMYWALLET Sep. 5 at 1:40 PM
$LGVN I'd say they'll announce some good news next week
0 · Reply